Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIRADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus MIRADON.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs MIRADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inhibition of coagulation factors, primarily thrombin (factor IIa) and factor Xa, thereby preventing clot formation and propagation.
MIRADON (anagrelide) inhibits cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipids, possibly by inhibiting phospholipase A2. It also suppresses megakaryocyte maturation and platelet production.
Intravenous: Initial bolus of 80 units/kg, followed by continuous infusion at 18 units/kg/hour. Titrate to achieve aPTT of 1.5-2.5 times control or anti-Xa level of 0.3-0.7 units/mL.
2.5 mg orally twice daily (total daily dose 5 mg)
None Documented
None Documented
1-2 hours (dose-dependent); extends to 2.5-4 hours with continuous infusion or renal impairment; clinical context: monitoring via aPTT required
Terminal elimination half-life is 8-12 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 20-30 hours. The half-life supports twice-daily dosing in most patients.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Renal excretion of unchanged drug accounts for 60-70% of the administered dose. Fecal/biliary excretion accounts for 20-25%, with the remainder as oxidative metabolites. Up to 10% is eliminated as glucuronide conjugates.
Category A/B
Category C
Anticoagulant
Anticoagulant